可溶性BDCA-2作为类风湿关节炎潜在生物标志物及其通过核酸结合增强IFN-α产生的作用
研究检测了RA(n=14)、SLE(n=14)患者及健康对照(n=15)血清中solBDCA-2与IFN-α表达,发现IFN-α在RA和SLE患者血清中均上调,而solBDCA-2仅在RA患者血清中上调、SLE中未上调。solBDCA-2可与TLR9配体CpG-ODN 2006及TLR3配体poly I:C结合形成复合物,增强CAL-1细胞和人PBMC的I型IFN产生。
要点
- RA患者血清solBDCA-2上调,SLE患者未见上调。
- RA与SLE患者血清IFN-α均上调。
- solBDCA-2与CpG-ODN 2006及poly I:C结合增强I型IFN产生。
核心结论
- solBDCA-2通过与DNA和RNA形成免疫刺激性复合物增强I型干扰素产生。
- solBDCA-2表达失调可能参与RA发病机制。
研究设计与样本
- ELISA检测RA患者(n=14)、SLE患者(n=14)及健康对照(n=15)血清solBDCA-2与IFN-α表达。
- 机制研究分析solBDCA-2与核酸的相互作用及其在CAL-1浆细胞样树突状细胞系和人外周血单个核细胞(hPBMC)中对I型IFN产生的增强作用。
主要发现
- IFN-α在RA和SLE患者血清中均上调。
- solBDCA-2仅在RA患者血清中上调,SLE患者中未上调。
- solBDCA-2与TLR9配体磷酸二酯CpG-寡脱氧核苷酸(ODN)2006及TLR3配体poly I:C相互作用形成复合物。
- 该复合物增强CAL-1细胞和hPBMC中I型IFN的产生。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Aberrant interferon (IFN) signalling is strongly associated with rheumatic diseases, particularly rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Blood dendritic cell antigen 2 (BDCA-2) regulates IFN production in plasmacytoid dendritic cells (pDCs). While heparin inhibits IFN formation via triggering surface BDCA-2, its soluble form (solBDCA-2) antagonizes heparin and thereby drives excessive IFN formation. However, the role of solBDCA-2 in RA and SLE is unknown. This study aims to determine whether solBDCA-2 can serve as a biomarker for RA and/or SLE and provide insights into its potential role in disease mechanisms. METHODS: solBDCA-2 and IFN-α expression were analysed by ELISA in the serum of RA (n = 14) and SLE (n = 14) patients and compared with healthy controls (n = 15). To gain mechanistic insight of solBDCA-2 in RA and SLE, we studied the interaction of solBDCA-2 with nucleic acids, its role in enhancing type I IFN production in the plasmacytoid dendritic cell line CAL-1 and in human peripheral blood mononuclear cells (hPBMCs). RESULTS: IFN-α was upregulated in patient sera of both RA and SLE. In contrast, solBDCA-2 was exclusively upregulated in the serum of RA patients, but not in patients with SLE. solBDCA-2 interacted with phosphodiester CpG-oligodeoxynucleotides (ODN) 2006, a ligand of TLR9, and poly I:C, a ligand of TLR3, to form complexes that enhance type I IFN production in CAL-1 cells and hPBMCs. CONCLUSION: These findings show that solBDCA-2 enhances type I interferon production by forming immunostimulatory complexes with DNA and RNA. Dysregulated solBDCA-2 expression might contribute to RA pathogenesis.
引用
- Mainieri L, Kaufmann A, Bucci L, et al. Soluble BDCA-2 as a potential biomarker for rheumatoid arthritis and its role in enhancing IFN-α production through nucleic acid binding. Rheumatology (Oxford). 2026. PMID: 41100072. doi:10.1093/rheumatology/keaf537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。